SVRA Savara |
$4.22 -7.0% |
November 22, 2026
|
Molgramostim (IMPALA-2)
Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
|
4/15/2026 - PDUFA Date
Savara Inc. announced Prescription Drug User Fee Act (PDUFA) Target Action Date Extended by Three Mo… Full Summary
|
CAPR Capricor Therapeutics |
$5.93 -3.3% |
November 22, 2026
|
Deramiocel
For the Treatment of Duchenne Muscular Dystrophy
|
BLA
|
8/24/2026 - PDUFA Date
Capricor Therapeutics announced that the U.S. Food and Drug Administration (FDA) has extended the Pr… Full Summary
|
BBIO BridgeBio Pharma |
$68.56 +0.6% |
November 27, 2026
|
BBP-418
Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)
|
|
5/27/2026 - PDUFA Date
BridgeBio Announces that The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target actio… Full Summary
|
COGT Cogent Biosciences |
$31.21 -0.3% |
November 30, 2026
|
bezuclastinib
In patients with non-advanced systemic mastocytosis
|
NDA
|
5/28/2026 - PDUFA Date
Cogent Biosciences, Inc announced The FDA has granted the application Priority Review and assigned … Full Summary
|
COGT Cogent Biosciences |
$31.21 -0.3% |
December 30, 2026
|
bezuclastinib
In patients with non-advanced systemic mastocytosis
|
NDA
|
3/16/2026 - PDUFA Date
Cogent Biosciences, Inc announced that the Prescription Drug User Fee Act (PDUFA) target action date… Full Summary
|
ANNX Annexon |
$3.75 -1.6% |
H2 2026
|
ANX007
Geographic Atrophy
|
|
9/9/2024 - Data
Annexon, Inc. announced that ARCHER II Phase 3 Pivotal Program in GA Underway with Data Expected Se… Full Summary
|
ANNX Annexon |
$3.75 -1.6% |
H2 2026
|
ANX007
Geographic Atrophy
|
Phase 3
|
12/5/2024 - Provided Update
Annexon, Inc. Pivotal Phase 3 ARCHER II in GA Actively Enrolling with Data Expected Second Half 2026 Full Summary
|
KNSA Kiniksa Pharmaceuticals International |
$76.73 -5.0% |
H2 2026
|
KPL-387
In recurrent pericarditis
|
Phase 2
|
6/5/2025 - Data
Kiniksa Pharmaceuticals International announced that Phase 2 data expected in 2H 2026 Full Summary
|
RNA Avidity Biosciences |
$8.20 +0.5% |
H2 2026
|
Delpacibart Braxlosiran
In People Living with Facioscapulohumeral Muscular Dystrophy
|
BLA
|
6/9/2025 - BLA Filing
Avidity Biosciences, Inc. announced that Planning accelerated approval BLA submission in H2 2026 Full Summary
|
RGNX REGENXBIO |
$6.68 -6.8% |
Q4 2026
|
surabgene lomparvovec
for Wet AMD
|
|
10/6/2025 - Top-line data
REGENXBIO Inc. announced that Topline pivotal data expected in Q4 2026 Full Summary
|
ACET Adicet Bio |
$3.99 -6.8% |
H2 2026
|
ADI-001
B cell non-Hodgkin's lymphoma (NHL)
|
Phase 1
|
10/16/2025 - Preclinical Data
Adicet Bio, Inc. announced that Preliminary clinical data from the Phase 1 trial expected in 2H/2026 Full Summary
|
VRCA Verrica Pharmaceuticals |
$3.53 -7.8% |
Q4 2026
|
YCANTH™ (cantharidin)
For molluscum contagiosum, which is primarily a pediatric disease.
|
|
10/20/2025 - Provided Update
Verrica is initiating activities to support this regulatory submission, which could be filed as earl… Full Summary
|
MIRM Mirum Pharmaceuticals |
$80.39 -3.3% |
Q4 2026
|
Maralixibat
Alagille Syndrome
|
|
3/16/2026 - Top-line data
Mirum Pharmaceuticals, Inc. announced that the Topline data expected in Q4 2026 Full Summary
|
ACRS Aclaris Therapeutics |
$3.75 -2.1% |
Q4 2026
|
ATI-045
In Atopic Dermatitis (AD)
|
|
3/18/2026 - Top-line results
Aclaris Therapeutics, Inc. announced that the Top line results are expected in the fourth quarter o… Full Summary
|
ENTA Enanta Pharmaceuticals |
$11.64 +0.2% |
Q4 2026
|
EDP-978
Treatment of Urticaria
|
|
4/13/2026 - Top-line data
Enanta Pharmaceuticals, Inc announced that the Topline Data Expected in Q4 2026 Full Summary
|
BBIO BridgeBio Pharma |
$68.56 +0.6% |
H2 2026
|
BBO-11818
Potent panKRAS Inhibitor
|
|
4/20/2026 - Clinical Data
BridgeBio Oncology Therapeutics, Inc. announced that the Updated Phase 1 clinical data are expected … Full Summary
|
ADCT ADC Therapeutics |
$1.45 -9.7% |
Q4 2026
|
ZYNLONTA
In patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
|
|
6/30/2026 - Data
ADC Therapeutics SA announced that the Full data expected in fourth quarter of 2026 Full Summary
|
PFE Pfizer |
$30.04 -1.3% |
Q4 2026
|
TALZENNA
Oral inhibitor of poly ADP-ribose polymerase
|
supplemental New Drug Application (sNDA) Priority Review
|
7/22/2026 - PDUFA Date
Pfizer Inc announced that the FDA has set a Prescription Drug User Fee Act (PDUFA) action date in … Full Summary
|
NAMS NewAmsterdam Pharma |
$19.71 -8.7% |
H2 2026
|
Obicetrapib
CETP inhibitor
|
|
7/24/2026 - Provided Update
NewAmsterdam Pharma Company N.V announced that the European Commission decision expected in 2H26 Full Summary
|
EYPT Eyepoint Pharmaceuticals |
$0.40 -5.5% |
Q4 2026
|
DURAVYU
In patients with non-proliferative diabetic retinopathy (NPDR).
|
|
8/17/2026 - Top-line data
EyePoint, Inc. announced that the Topline data from LUCIA, the second pivotal Phase 3 clinical trial… Full Summary
|
ACET Adicet Bio |
$3.99 -6.8% |
Q4 2026
|
ADI-212
treatment of patients with metastatic castration-resistant prostate cancer
|
Phase 1
|
8/27/2026 - Initiation
Adicet Bio, Inc. announced that The Company plans to initiate Phase 1 enrollment in patients with m… Full Summary
|
COCP Cocrystal Pharma |
$0.95 +4.2% |
LATE 2026
|
CDI-988
For Pandemic Norovirus and Coronavirus
|
|
9/9/2026 - Results
Cocrystal Pharma, Inc announced that the Preliminary efficacy results expected in late 2026 or ea… Full Summary
|
PRLD Prelude Therapeutics |
$3.63 +0.8% |
Q4 2026
|
PRT13722
Oral KAT6A Selective Degrader
|
|
9/10/2026 - Enrollment Update
Prelude Therapeutics Incorporated announced that the Company expects to begin enrolling patients in… Full Summary
|
CAMP CAMP4 Therapeutics |
$3.30 -2.7% |
Q4 2026
|
CMP-002
treat a broad range of genetic diseases
|
|
9/10/2026 - Clinical Trial
CAMP4 Therapeutics Corporation announced that the Company anticipates initiation of the clinical tr… Full Summary
|
LPCN Lipocine |
$1.44 -1.4% |
Q4 2026
|
LPCN 1154
Postpartum depression (PPD)
|
|
9/14/2026 - Dose Update
Lipocine Inc announced that the first participant dosing expected in early Q4 2026 Full Summary
|
TNYA Tenaya Therapeutics |
$0.39 +0.3% |
Q4 2026
|
TN-401
For the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by Plakophilin-2 (PKP2) gene mutations.
|
|
9/14/2026 - Additional data
Tenaya Therapeutics, Inc. announced Additional Data and Updates on Regulatory Discussions Anticipat… Full Summary
|
OCUL Ocular Therapeutix |
$6.50 -1.7% |
Q4 2026
|
AXPAXLI
In Diabetic Retinopathy
|
|
9/15/2026 - NDA submission
Ocular Therapeutix, Inc announced that it remains on track to submit the NDA in the fourth quarter … Full Summary
|
ORKA Oruka Therapeutics |
$80.15 -1.2% |
December 1, 2026
|
ORKA-001
Inhibitor IL-23p19
|
|
9/23/2026 - Data
Oruka Therapeutics, announced that the 52-week EVERLAST-A data for all patients expected in Decembe… Full Summary
|
ORKA Oruka Therapeutics |
$80.15 -1.2% |
Q4 2026
|
ORKA-001
Inhibitor IL-23p19
|
|
9/23/2026 - Data
Oruka Therapeutics, announced that the 16-week EVERLAST-B data expected in 4Q 2026 Full Summary
|
LIFE Ethos Technologies Inc. Class A Common Stock |
$43.10 -1.0% |
Q4 2026
|
Efzofitimod
Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
|
|
9/24/2026 - Provided Update
aTyr Pharma, Inc. announced that the Company expects to initiate study-related activities in the fo… Full Summary
|
PRLD Prelude Therapeutics |
$3.63 +0.8% |
Q4 2026
|
PRT13722
Oral KAT6A Selective Degrader
|
|
10/13/2026 - Enrollment Update
Prelude Therapeutics Incorporated announced that its on track to initiate enrollment in the fourth… Full Summary
|
TRDA Entrada Therapeutics |
$4.41 -6.8% |
LATE 2026
|
ELEVATE-44-201
For Duchenne Muscular Dystrophy
|
|
10/14/2026 - Data
Entrada Therapeutics, Inc. announced that the Company to receive ELEVATE-44-201 data from Cohort 1 … Full Summary
|
AQST Aquestive Therapeutics |
$4.00 -3.1% |
Q4 2026
|
Anaphylm
For epinephrine prodrug candidate product
|
|
10/15/2026 - Provided Update
Aquestive Therapeutics, Inc. announced that the Ex-U.S. strategy remains on track with Canadian N… Full Summary
|
SMMT Summit Therapeutics |
$15.47 -0.5% |
Q4 2026
|
Ivonescimab
For Lung cancer
|
|
10/21/2026 - Clinical Trial
Summit Therapeutics Inc. announced Clinical Trial Site Activations in the United States Expected … Full Summary
|
NUVB Nuvation Bio |
$4.57 -2.9% |
January 4, 2027
|
IBTROZI
In Advanced ROS1-Positive Non-Small Cell Lung Cancer
|
supplemental New Drug Application (sNDA)
|
5/6/2026 - PDUFA Date
Nuvation Bio Inc announced today that the U.S. Food and Drug Administration (FDA) has accepted a sup… Full Summary
|
INSM Insmed |
$93.39 -1.8% |
January 28, 2027
|
ARIKAYCE®
IN PATIENTS WITH NTM LUNG DISEASE CAUSED BY MAC
|
supplemental New Drug Application (sNDA)
|
9/21/2026 - PDUFA Date
Insmed Incorporated announced that the FDA granted Priority Review to the sNDA and set a target act… Full Summary
|
PHAR Pharming Group |
$11.20 +5.0% |
January 30, 2027
|
Leniolisib
Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)
|
supplemental New Drug Application (sNDA)
|
9/25/2026 - PDUFA Date
Pharming announced that The application has been granted Priority Review and assigned a Prescriptio… Full Summary
|
BLTE Belite Bio |
$147.33 -2.0% |
February 12, 2027
|
Tinlarebant
In Stargardt Disease
|
|
8/11/2026 - PDUFA Date
Belite Bio, Inc announced that The FDA has set a Prescription Drug User Fee Act (PDUFA) date of Feb… Full Summary
|
CGEM Cullinan Therapeutics |
$14.37 -3.7% |
February 27, 2027
|
zipalertinib
For patients with heavily pre-treated EGFR ex20ins mutation NSCLC
|
NDA
|
4/28/2026 - PDUFA Date
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, announced that The… Full Summary
|
BMRN BioMarin Pharmaceutical |
$55.95 -1.2% |
February 28, 2027
|
vosoritide
Children with achondroplasia
|
supplemental New Drug Application (sNDA)
|
7/13/2026 - PDUFA Date
BioMarin Pharmaceutical Inc. announced that The FDA has set a Prescription Drug User Fee Act (PDUFA… Full Summary
|
INMB INmune Bio |
$1.46 -5.2% |
February 1, 2027
|
Ebstrocel
rare and severe genetic skin
|
|
10/21/2026 - Marketing authorization
INmune Bio Inc. announced that the Full MAA submission targeted for early February 2027 Full Summary
|
NTLA Intellia Therapeutics |
$11.21 +0.4% |
March 10, 2027
|
onvo-z
hereditary angioedema
|
BLA
|
9/8/2026 - PDUFA Date
Intellia Therapeutics, announced that the PDUFA target action date of March 10, 2027 Full Summary
|
AQST Aquestive Therapeutics |
$4.00 -3.1% |
March 16, 2027
|
Anaphylm
For epinephrine prodrug candidate product
|
NDA
|
10/15/2026 - PDUFA Date
Aquestive Therapeutics, Inc. announced that the Prescription Drug User Fee Act (PDUFA) goal action… Full Summary
|
MRK Merck & Co., Inc. |
$145.25 -1.4% |
March 22, 2027
|
ENFLONSIA™
In Infants Born During or Entering Their First RSV Season
|
sBLA
|
8/6/2026 - PDUFA Date
Merck announced that The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, dat… Full Summary
|
PMVP PMV Pharmaceuticals |
$1.27 -2.7% |
Q1 2027
|
rezatapopt
in patients with advanced solid tumors
|
NDA
|
10/24/2025 - NDA Filing
PMV Pharmaceuticals, announced that Full Summary
|
STOK Stoke Therapeutics |
$25.04 -2.6% |
Q1 2027
|
zorevunersen
For the treatment of Dravet syndrome with a confirmed mutation,
|
|
6/30/2026 - rolling submission
Stoke Therapeutics, Inc to initiate a rolling New Drug Application (NDA) submission to the U.S. Food… Full Summary
|
ABEO Abeona Therapeutics |
$4.40 -1.6% |
Q1 2027
|
PMN310
PMN310 is a novel monoclonal antibody
|
|
7/28/2026 - Top-line results
ProMIS Neurosciences Inc. announced that 12-month topline results expected in Q1 2027 Full Summary
|
TEVA Teva Pharmaceutical Industries |
$39.39 -2.0% |
Q1 2027
|
Ecopipam
To Treat Pediatric Patients With Tourette Syndrome
|
NDA
|
8/19/2026 - PDUFA Date
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd announced that the U.S.… Full Summary
|
DYN Dyne Therapeutics |
$15.62 -1.0% |
Q1 2027
|
DYNE-101
Designed to enable targeted muscle tissue delivery with the goal of reducing toxic DMPK RNA in the nucleus
|
|
9/8/2026 - Top-line data
Dyne Therapeutics, Inc. announced that the Topline data from the ACHIEVE REC are on track for Q1 20… Full Summary
|
TAK Takeda Pharmaceutical |
$20.26 -0.5% |
Q1 2027
|
TAK-279
For the Treatment of Active Psoriatic Arthritis
|
NDA
|
9/14/2026 - PDUFA Date
Takeda announced that the Prescription Drug User Fee Act (PDUFA) target action date is in the first … Full Summary
|
PALI Palisade Bio |
$1.33 -1.5% |
Q1 2027
|
PALI-2108
For patients affected by UC.
|
|
9/22/2026 - Dose Update
Palisade Bio, Inc. announced that First patient dosing targeted for Q1 2027 Full Summary
|
BLSM BlossomHill Therapeutics |
$14.63 -7.5% |
Q1 2027
|
BH-501284
Novel Pan-KRAS Inhibitor
|
IND
|
9/28/2026 - IND Submission
BlossomHill Therapeutics, Inc. announced that the IND submission in Q1 2027 Full Summary
|
TRDA Entrada Therapeutics |
$4.41 -6.8% |
Q1 2027
|
ELEVATE-44-201
For Duchenne Muscular Dystrophy
|
|
10/14/2026 - Enrollment Update
Entrada Therapeutics, Inc. announced that the Cohort 2 enrollment complete with data expected in Q1… Full Summary
|
JSPR Jasper Therapeutics |
$0.51 +2.9% |
Q1 2027
|
vensobafusp alfa
IgA Nephropathy
|
|
10/15/2026 - Expansion
Jasper Therapeutics, announces expansion cohort in patients with FSGS, with first patients anticipat… Full Summary
|
TLSA Tiziana Life Sciences |
$0.95 -5.0% |
Q1 2027
|
intranasal foralumab
Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
|
|
10/16/2026 - Top-line data
Tiziana Life Sciences, Ltd. announced that Topline data are anticipated to be announced in Q1 2027. Full Summary
|
DMAC DiaMedica Therapeutics |
$8.72 +1.0% |
Q1 2027
|
DM199
Chronic Kidney Disease Stage II or III
|
|
10/22/2026 - Analysis
DiaMedica Therapeutics Inc announced that the Interim Analysis Results Expected in Q1 2027 Full Summary
|
PHVS Pharvaris |
$31.41 +2.4% |
April 23, 2027
|
Deucrictibant
For bradykinin-B2-receptor
|
|
7/6/2026 - PDUFA Date
Pharvaris announced that The FDA has set a Prescription Drug User Fee Act (PDUFA) target action dat… Full Summary
|
ORGO Organogenesis |
$0.99 -3.6% |
April 27, 2027
|
ReNu
for Knee Osteoarthritis
|
|
7/6/2026 - PDUFA Date
Organogenesis Holdings Inc. announced that the FDA has set a Prescription Drug User Fee Act (PDUFA) … Full Summary
|
AXSM Axsome Therapeutics |
$145.04 -7.1% |
May 1, 2027
|
AXS-12
Narcolepsy
|
|
7/15/2026 - PDUFA Date
Axsome Therapeutics, Inc. announced that the FDA sets PDUFA target action date of May 1, 2027 Full Summary
|
BBIO BridgeBio Pharma |
$68.56 +0.6% |
May 8, 2027
|
Encaleret
Autosomal Dominant Hypocalcemia Type 1 (ADH1)
|
NDA
|
7/22/2026 - PDUFA Date
BridgeBio Pharma, Inc. announced that The FDA has assigned a Prescription Drug User Fee Act (PDUFA) … Full Summary
|
BMY Bristol Myers Squibb |
$61.58 -2.3% |
May 13, 2027
|
MeziKd
Relapsed or Refractory Multiple Myeloma
|
NDA
|
7/13/2026 - PDUFA Date
Bristol Myers Squibb announced that The U.S. FDA has assigned a target action date of May 13, 2027 Full Summary
|
URGN Urogen Pharma |
$34.49 -1.9% |
June 14, 2027
|
UGN-103
For Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
|
NDA
|
10/19/2026 - PDUFA Date
UroGen Pharma Ltd. announced that The FDA has assigned a Prescription Drug User Fee Act (PDUFA) ta… Full Summary
|
COGT Cogent Biosciences |
$31.21 -0.3% |
June 29, 2027
|
bezuclastinib
In patients with non-advanced systemic mastocytosis
|
NDA
|
9/15/2026 - PDUFA Date
Cogent Biosciences, Inc. announced that the assigned a Prescription Drug User Fee Act (PDUFA) target… Full Summary
|
NBTX Nanobiotix |
$29.36 +0.6% |
H1 2027
|
NANORAY-312
head and neck squamous cell cancers.
|
|
10/24/2025 - Interim Data
Nanobiotix estimates that NANORAY-312 interim data will be analyzed and reported, after both the req… Full Summary
|
KOD Kodiak Sciences |
$87.63 +2.2% |
Q2 2027
|
KSI-101
in patients with MESI
|
|
8/6/2026 - Top-line data
Kodiak Sciences Inc. announced that the topline clinical data release anticipated in 2Q 2027 Full Summary
|
EYPT Eyepoint Pharmaceuticals |
$0.40 -5.5% |
H1 2027
|
DURAVYU
In patients with non-proliferative diabetic retinopathy (NPDR).
|
|
8/17/2026 - NDA submission
EyePoint, Inc. announced that the potential FDA New Drug Application submission planned for 1H 2027 Full Summary
|
VOR Vor Biopharma |
$18.26 -3.6% |
H1 2027
|
telitacicept
Sjögren's Disease
|
|
9/8/2026 - Top-line results
Vor Bio announced Topline results from the 24-week primary endpoint remain expected in the first ha… Full Summary
|
OPTH Optimi Health |
$3.25 -0.9% |
H1 2027
|
psilocybin-assisted therapy
for Major Depressive Disorder
|
|
9/10/2026 - Trial Initiation
Optimi Health Corp announced that the trial is planned to be initiated in the first half of 2027 Full Summary
|
OGN Organon & Co. |
$13.76 +0.0% |
Q2 2027
|
MIUDELLA
Hormone-Free Intrauterine Device
|
|
9/14/2026 - PDUFA Date
Organon announced that the Prescription Drug User Fee Act (PDUFA) action expected in the second quar… Full Summary
|
COCH Envoy Medical |
$0.60 -0.1% |
Q2 2027
|
Acclaim
for Breakthrough Hearing Device
|
|
10/12/2026 - Provided Update
Envoy Medical® announced that the Advances Toward Targeted Completion of the Final Clinical Module … Full Summary
|
QNRX Quoin Pharmaceuticals |
$4.07 +1.4% |
Q2 2027
|
QRX003
Nethertons Syndrome
|
|
10/20/2026 - Top-line data
Quoin Pharmaceuticals Ltd. announced that the Topline Data Expected in Q2 2027 Full Summary
|
JBIO Jade Biosciences |
$14.59 -2.1% |
Q2 2027
|
JADE101
For the treatment of IgA nephropathy (IgAN)
|
|
10/21/2026 - Highlights
Jade Biosciences, Inc. announced that the JUNIPER Phase 2 Trial-in-Progress poster highlights ongoi… Full Summary
|
INMB INmune Bio |
$1.46 -5.2% |
Q2 2027
|
Ebstrocel
rare and severe genetic skin
|
BLA
|
10/21/2026 - Provided Update
INmune Bio Inc. announced that the U.S. BLA expected to be submitted in Q2, 2027 Full Summary
|
CLYM Climb Bio |
$10.19 -3.3% |
H1 2027
|
CLYM116
for IgAN
|
|
10/23/2026 - Initial Data
Climb Bio, Inc. announced that the NAVIGATE-2 Phase 2 trial enrolling, with initial data expected in… Full Summary
|
GTBP GT Biopharma |
$5.46 -1.1% |
Q3 2027
|
GTB-5550
Multiple Myeloma
|
Phase 1
|
9/15/2026 - Dose escalation
GT Biopharma, Inc announced that the Phase 1 dose escalation basket trial with GTB-5550 in solid t… Full Summary
|
LBRX LB Pharmaceuticals |
$38.73 -1.8% |
H2 2027
|
LB-102
In Patients With Bipolar Depression
|
|
3/25/2026 - Top-line data
LB Pharmaceuticals Inc announced that the Topline data expected in 2H 2027 Full Summary
|
AURA Aura Biosciences |
$6.30 -2.5% |
H2 2027
|
Belzupacap Sarotalocan (AU-011)
Non-Muscle Invasive Bladder Cancer (NMIBC)
|
|
6/1/2026 - Top-line data
Aura Biosciences Announced that the Topline data for the 15-month primary endpoint are anticipated… Full Summary
|
IONS Ionis Pharmaceuticals |
$42.93 -2.2% |
H2 2027
|
ION582
Angelman syndrome
|
|
7/6/2026 - Top-line data
Ionis Pharmaceuticals, Inc announced Topline data from REVEAL anticipated in 2H 2027 - Full Summary
|
EYPT Eyepoint Pharmaceuticals |
$0.40 -5.5% |
Q4 2027
|
DURAVYU
In patients with non-proliferative diabetic retinopathy (NPDR).
|
|
7/30/2026 - Top-line data
EyePoint, Inc. announced that Topline data for both DME trials are anticipated in the fourth quart… Full Summary
|
OPTH Optimi Health |
$3.25 -0.9% |
LATE 2027
|
psilocybin-assisted therapy
for Major Depressive Disorder
|
|
9/10/2026 - Dose Update
Optimi Health Corp. announced that the dosing expected to be complete by the end of 2027. Full Summary
|
ALKS Alkermes |
$43.63 -1.2% |
LATE 2027
|
ALKS 7290
in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
|
Phase 2
|
9/21/2026 - Data
Alkermes plc announced that the Phase 2 Study of ALKS 7290 in Adults With ADHD is Enrolling, Data Ex… Full Summary
|
EDSA Edesa Biotech |
$2.77 +0.4% |
Q4 2027
|
EB06
Moderate-To-Severe Nonsegmental Vitiligo
|
|
10/15/2026 - Top-line data
Edesa anticipates that topline data will be available fourth quarter 2027. Full Summary
|
STRO Sutro Biopharma |
$9.33 -9.3% |
H2 2027
|
STRO-006
In Patients With Range Of Solid Tumors
|
|
10/21/2026 - Initial Data
Sutro Biopharma, Inc announced that the Initial clinical data expected in the second half of 2027 Full Summary
|
PALI Palisade Bio |
$1.33 -1.5% |
Q1 2028
|
PALI-2108
For patients affected by UC.
|
|
9/22/2026 - primary efficacy readout
Palisade Bio, Inc. announced that primary efficacy readout (Week 12 endoscopic response) targeted … Full Summary
|